What Did the Studies Show?In the primary PROVENGE study, men who received PROVENGE survived an average of 4.1 months longer than men who received the placebo medication. More specifically, the PROVENGE group survived an average of 25.8 months after beginning treatment, compared to 21.7 months in the placebo group. PROVENGE also reduced the risk of death by 22.5 percent compared to the placebo.
In two smaller studies, men who were given PROVENGE also appeared to survive longer than men given a control medication. However, in one of these studies, the difference in survival time was not large enough to say for certain that PROVENGE was effective.
It should also be noted that in all of the studies, prostate cancer progressed just as quickly in men given PROVENGE as it did in men given the control medication. It is not entirely clear why PROVENGE was effective at prolonging survival, but not in slowing down the progression of the cancer.
Keep in mind that medications are sometimes more or less effective in clinical practice than they appear to be in clinical trials. This can happen if people given the medication in real-life settings are different from those given the medicine in the clinical studies. Therefore, there may be additional information that is discovered about the effectiveness of PROVENGE once it is used in clinical practice.
Final ThoughtsYou should talk with your healthcare provider if you have questions about the potential effectiveness of PROVENGE for your individual situation. Although it is impossible for your healthcare provider to predict how well you will respond to this medication, after considering what you want and expect from treatment, your healthcare provider can give you an idea of whether PROVENGE is a viable treatment option for you.